MITSUBISHI-HITACHI-POWER
Mitsubishi Hitachi Power Systems, Ltd. (MHPS) has begun commissioning of T-Point 2, its new combined cycle power plant validation facility at Takasago Works in Hyogo Prefecture, Japan. Replacing the iconic T-Point, the facility will accelerate MHPS’ industry-leading technology and enable more robust validation of advanced-class gas turbines (ACGTs) such as the 1650°C-class JAC model and 1700°C-class ultrahigh-temperature models. Like its predecessor, T-Point 2 stands apart as the only facility in the world that performs full-scale long-term reliability verification for gas turbines. Connected to the actual grid, it is the only plant of its type in the world to function as both a technology demonstrator and an electric power producer and supplier. Also housed within Takasago Works are centers for R&D, design, manufacturing, and short-term component testing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200401005834/en/
“Through the years, we have proven our ability to develop and manufacture the most cutting-edge solutions for the power generation industry,” said Mr. Ken Kawai, President and CEO, MHPS. “Building on the legacy of the original T-Point, T-Point 2 will enable us to widen our footprint as the preferred solutions partner to meet ever-changing power generation requirements around the world.”
Engineering the next generation of gas turbines
Once commercial operations begin in July 2020, T-Point 2 is expected to achieve power output of over 566 MW (60Hz), with nearly 64% efficiency, 99.5% reliability and a world-first turbine inlet temperature of 1650°C – raising industry standards for gas turbine combined cycle performance globally. This improved performance is possible due to the advanced engineering of the upgraded J-Series Air-Cooled (JAC) model, which is the first gas turbine being validated at T-Point 2.
The new facility features a triple-casing steam turbine, augmenting overall system efficiency through a multiplier effect with the JAC gas turbine. This greater efficiency reduces carbon emissions and heat loss, significantly reducing the environmental impact of T-Point 2.
“The prototype validation system established by MHPS has given our customers the clear assurance that they are receiving the highest caliber and most reliable energy solutions in the market,” said Mr. Junichiro Masada, Senior Vice President and Senior General Manager of Gas Turbine Technology & Products Integration Division, MHPS. “The launch of T-Point 2 is testament to MHPS’ commitment to deliver industry-leading power generation technology and customer service underpinned by best-in-class methods for performance and durability verification.”
MHPS will use the facility to conduct validation of the next-generation 1700°C-class ultrahigh-temperature gas turbines, steam turbine upgrades, air-cooled condenser technology, generators, and static frequency converters.
Bringing power generation to the digital age
Work is underway to install and train advanced artificial intelligence technology at T-Point 2, which will feature the MHPS-TOMONI®
suite of digital solutions. During the 8,000 hour durability demonstration period, MHPS will also be training its AI apps, allowing T-Point 2 to eventually become the world’s first autonomous combined cycle power plant. This will catapult power generation into a future where digital technologies are fully integrated into plant operations, allowing plant owners to leverage data to optimize performance, enable condition-based predictive maintenance for equipment, selectively automate operation and maintenance (O&M) decision-making, and reduce risk.
With these building blocks, MHPS will remotely monitor and manage total plant performance; remotely operate the plant in coordination with grid and fleet-wide energy management objectives; and utilize sensor and control system data to make smarter operation decisions in real time. MHPS-TOMONI® solutions powered by advanced technologies such as artificial intelligence and machine learning will enable MHPS to automate O&M decision-making to maximize the profitability of existing and future GTCC plants.
About Mitsubishi Hitachi Power Systems, Ltd.
Mitsubishi Hitachi Power Systems, Ltd. (MHPS), headquartered in Yokohama, Japan, is a joint venture formed in February 2014 by Mitsubishi Heavy Industries, Ltd. and Hitachi, Ltd. integrating their operations in thermal power generation systems and other related businesses. MHPS today ranks among the world’s leading suppliers of equipment and services to the power generation market, backed by 100 billion yen in capital and approximately 20,000 employees worldwide. The Company’s products include GTCC (gas turbine combined-cycle) and IGCC (integrated coal gasification combined-cycle) power plants, gas/coal/oil-fired (steam) power plants, boilers, generators, gas and steam turbines, geothermal power plants, AQCS (air quality control systems), power plant peripheral equipment and solid-oxide fuel cells (SOFC). For more information, please visit the Company's website at https://www.mhps.com
. Follow us at https://twitter.com/MHPS_Global
, or http://www.linkedin.com/showcase/mhps
View source version on businesswire.com: https://www.businesswire.com/news/home/20200401005834/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom